Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIVE Immune Modulation Trial (Abatacept for Hospitalized COVID-19)
2023-504487-41-00Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Oct 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 28
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing ORENCIA plus standard of care with Saline plus standard of care (2 arms). Primary endpoint: Days to Recovery Scale over 60 days (DRS-60). Started Oct 2023; status: completed.
02
Drugs
abatacept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-504487-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504487-41-00.